338 related articles for article (PubMed ID: 33289297)
61. Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.
Johansen NJ; Dejgaard TF; Lund A; Vilsbøll T; Andersen HU; Knop FK
BMJ Open; 2018 Jun; 8(6):e021861. PubMed ID: 29950475
[TBL] [Abstract][Full Text] [Related]
62. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
[TBL] [Abstract][Full Text] [Related]
63. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Battelino T; Bergenstal RM; Rodríguez A; Fernández Landó L; Bray R; Tong Z; Brown K
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):407-417. PubMed ID: 35468321
[TBL] [Abstract][Full Text] [Related]
64. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
Libman IM; Miller KM; DiMeglio LA; Bethin KE; Katz ML; Shah A; Simmons JH; Haller MJ; Raman S; Tamborlane WV; Coffey JK; Saenz AM; Beck RW; Nadeau KJ;
JAMA; 2015 Dec; 314(21):2241-50. PubMed ID: 26624824
[TBL] [Abstract][Full Text] [Related]
65. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Li K; Xu G
J Diabetes; 2019 Aug; 11(8):645-655. PubMed ID: 30565398
[TBL] [Abstract][Full Text] [Related]
66. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Lu J; Tang L; Meng H; Zhao J; Liang Y
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
[TBL] [Abstract][Full Text] [Related]
67. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.
Avgerinos I; Manolopoulos A; Michailidis T; Kitsios K; Liakos A; Karagiannis T; Dimitrakopoulos K; Matthews DR; Tsapas A; Bekiari E
Diabetes Obes Metab; 2021 Mar; 23(3):822-831. PubMed ID: 33300282
[TBL] [Abstract][Full Text] [Related]
68. Sodium/glucose cotransporter 2 inhibitors for the treatment of type 1 diabetes: what are the latest developments?
Veneti S; Tziomalos K
Expert Opin Pharmacother; 2021 Nov; 22(16):2261-2266. PubMed ID: 34402702
[TBL] [Abstract][Full Text] [Related]
69. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Tang H; Cui W; Li D; Wang T; Zhang J; Zhai S; Song Y
Diabetes Obes Metab; 2017 Jan; 19(1):142-147. PubMed ID: 27598833
[TBL] [Abstract][Full Text] [Related]
70. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
[TBL] [Abstract][Full Text] [Related]
71. Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m
Mathieu C; Dandona P; Birkenfeld AL; Hansen TK; Iqbal N; Xu J; Repetto E; Scheerer MF; Thoren F; Phillip M
Diabetes Obes Metab; 2020 Nov; 22(11):2151-2160. PubMed ID: 32691513
[TBL] [Abstract][Full Text] [Related]
72. Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?
Kamoshima H; Nomoto H; Yamashita K; Takahashi Y; Tsuchida K; Kuwabara S; Miya A; Cho KY; Kameda H; Nakamura A; Atsumi T; Taneda S; Kurihara Y; Aoki S; Ono Y; Miyoshi H
Endocr J; 2022 May; 69(5):495-509. PubMed ID: 34819409
[TBL] [Abstract][Full Text] [Related]
73. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
[TBL] [Abstract][Full Text] [Related]
74. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
[TBL] [Abstract][Full Text] [Related]
75. Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin.
Boeder S; Davies MJ; McGill JB; Pratley R; Girard M; Banks P; Pettus J; Garg S
Diabetes Technol Ther; 2024 May; ():. PubMed ID: 38441906
[No Abstract] [Full Text] [Related]
76. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
Pieber TR; Deller S; Korsatko S; Jensen L; Christiansen E; Madsen J; Heller SR
Diabetes Obes Metab; 2015 Aug; 17(8):742-50. PubMed ID: 25855340
[TBL] [Abstract][Full Text] [Related]
77. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Albarrán OG; Ampudia-Blasco FJ
Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
[TBL] [Abstract][Full Text] [Related]
78. Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
Koufakis T; Mustafa OG; Tsimihodimos V; Ajjan RA; Kotsa K
Drugs; 2021 Aug; 81(12):1365-1371. PubMed ID: 34232488
[TBL] [Abstract][Full Text] [Related]
79. Short- and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis.
Huang Y; Jiang Z; Wei Y
Endokrynol Pol; 2020; 71(4):325-333. PubMed ID: 32901912
[TBL] [Abstract][Full Text] [Related]
80. Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
Langford BE; Evans M; Haskins-Coulter T; O'Connor M; Cant HEO; Eddowes LA; Edmonds C; Tank A
Diabetes Obes Metab; 2020 Jan; 22(1):39-50. PubMed ID: 31468649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
